A recent study in a mouse model of colitis has demonstrated that interleukin (IL)-13, through inhibition of the mixed type 1 and type 17 T-helper cell inflammatory response, has a protective effect. the decoy receptor Il-13R alpha 2 inhibits this protective effect, suggesting blockade of IL-13R alpha 2 as a potential therapy for patients with IBD.
|Titolo:||IBD Of mice and men-shedding new light on IL-13 activity in IBD|
|Data di pubblicazione:||2011|
|Appare nelle tipologie:||1.1 Articolo in rivista|